Tradestie Institutional Equity Comparison Engine

EVMN vs EPRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EPRX Overall Edge

EPRX Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) driven by superior Growth & Margin, Momentum & Technical while EVMN counters with relative strength in Options & Structure. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EPRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against EPRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EVMN N/M vs EPRX N/M Fwd P/E
Growth & Margin Winner EPRX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner EPRX
1Y -61.0% vs +15.8% ยท 52W Pos 8% vs 46%
Options & Structure Winner EVMN
SURGE (53rd %ile IV) vs UNCLASSIFIED (N/A IV)
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
1M Return +37.33%
1Y Return -61.03%
Forward P/E N/M
Unified AI Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
EPRX NASDAQ
Eupraxia Pharmaceuticals Inc. Common Stock
Pharmaceutical Preparations
$7.34
-9.94% 1D
Market Cap $548.2M
1M Return +10.88%
1Y Return +15.77%
Forward P/E N/M
Unified AI Score
34.1 / 100 SELL
Tech 15.0 Fund 40.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EVMN -61.03% EPRX +15.77% Spread: +76.8 pp (EPRX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EVMN TTM Op. Margin: 0.0% EPRX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVMN vs EPRX. Trailing 12-month operating profitability (EVMN 0.0% vs EPRX 0.0%) and valuation multiples (EVMN N/M vs EPRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EVMN (0) vs EPRX (5)
Institutional Metric EVMN EPRX Criterion Row Winner
Market Capitalization Scale $315.5M $548.2M Larger Scale EPRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -69.5% -56.4% Higher ROE EPRX
52-Week Range Position Momentum 8% ($5โ€“$33) 46% ($6โ€“$9) Stronger Trend EPRX
Beta / 30D Volatility Risk Regime 1.05ฮฒ ยท 118% Vol 1.70ฮฒ ยท 76% Vol Lower Realized Risk EPRX
Unified Institutional Score Composite Signal 30.0 / 100 (SELL) 34.1 / 100 (SELL) Higher Composite EPRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EVMN vs EPRX Buy Guide
EVMN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 53rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EVMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EPRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EPRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EVMN nor EPRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.